The report is an essential source of information and analysis on the global Gastrointestinal Stromal Tumors industry . The report identifies the major industry developments shaping and driving the global Gastrointestinal Stromal Tumors industry . The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the industry positioning of the current industry leaders. Most importantly, the report provides valuable insights on the new product development within the global Gastrointestinal Stromal Tumors segment . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.

Scope of the Research

The report provides data on the key drivers and challenges of the Gastrointestinal Stromal Tumors industry . Its

Scope of the Research includes -
- Annualized seven key industry s (US, France, Germany, Italy, Spain, UK and Japan) Gastrointestinal Stromal Tumors industry revenues data from 2005 to 2009, projection for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key industry s. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Gastrointestinal Stromal Tumors industry .
- Insightful review of the key market drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, industry characterization, unmet needs and the implications for the Gastrointestinal Stromal Tumors therapeutics industry .
- Analysis of key recent licensing and partnership agreements in gastrointestinal stromal tumors industry

Why Should You Get This Report?

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of new product development and technologies and by identifying the industry players with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Gastrointestinal Stromal Tumors industry .
- Drive revenues by understanding the major industry developments, innovative products and technologies, industry sectors and industry players likely to impact the global Gastrointestinal Stromal Tumors industry in future.
- Formulate effective sales and industry ing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Gastrointestinal Stromal Tumors industry landscape? – Identify, understand and decide.

Table Of Contents

1 Table of contents

I Table of contents 2
I. 1 List of Data tables 4
I. 2 List of Charts 5

II Gastrointestinal Stromal Tumor (GIST) Therapeutics: Introduction 6
II. 1 Overview 6
II. 2 Epidemiology 6
II. 3 Symptoms 7
II. 4 Etiology 7
II. 5 Staging of GIST 8
II. 6 Diagnosis of GIST 9
II. 6.1 Computed Tomography Scan (CT scan) 9
II. 6.2 X-ray 9
II. 6.3 Magnetic Resonance Imaging (MRI) or Positron Emission Tomography (PET scan) 9
II. 6.4 Mutational Analysis 9
II. 7 Treatment of GIST 9
II. 7.1 Surgery 9
II. 7.2 Radiation Therapy 10
II. 7.3 Chemotherapy 10
II. 7.4 Targeted Therapy 10
II. 8 GlobalData Pipeline Report Guidance 11

III Gastrointestinal Stromal Tumor (GIST) Therapeutics: March ket Characterization 12
III. 1 GIST Therapeutics March ket Size (2005-2010) - World 12
III. 2 GIST Therapeutics March ket Forecasted data (2010-2017) - World 13
III. 3 GIST Therapeutics March ket Size (2005-2010) - The US 14
III. 4 GIST Therapeutics March ket Forecasted data (2010-2017) - The US 15
III. 5 GIST Therapeutics March ket Size (2005-2010) - France 16
III. 6 GIST Therapeutics March ket Forecasted data (2010-2017) - France 17
III. 7 GIST Therapeutics March ket Size (2005-2010) - Germany 18
III. 8 GIST Therapeutics March ket Forecasted data (2010-2017) - Germany 19
III. 9 GIST Therapeutics March ket Size (2005-2010) - Italy 20
III. 10 GIST Therapeutics March ket Forecasted data (2010-2017) - Italy 21
III. 11 GIST Therapeutics March ket Size (2005-2010) - Spain 22
III. 12 GIST Therapeutics March ket Forecasted data (2010-2017) - Spain 23
III. 13 GIST Therapeutics March ket Size (2005-2010) - The UK 24
III. 14 GIST Therapeutics March ket Forecasted data (2010-2017) - The UK 25
III. 15 GIST Therapeutics March ket Size (2005-2010) - Japan 26
III. 16 GIST Therapeutics March ket Forecasted data (2010-2017) - Japan 27
III. 17 Drivers and Barriers for the GIST Therapeutics March ket 28
III. 17.1 Drivers for the GIST Therapeutics March ket 28
III. 17.2 Barriers for the GIST Therapeutics March ket 28
III. 18 Opportunity and Unmet Need Analysis 29
III. 19 Key Takeaway 30

IV Gastrointestinal Stromal Tumor (GIST) Therapeutics: Competitive Assessment 31
IV. 1 Overview 31
IV. 2 Strategic Competitor Assessment 31
IV. 3 Product Profiles for the Major March keted Products in the GIST Therapeutics March ket 32
IV. 3.1 Gleevec (imatinib mesylate) 32
IV. 3.2 Sutent (sunitinib malate) 35
IV. 4 Key Takeaway 36

V Gastrointestinal Stromal Tumor (GIST) Therapeutics: Pipeline Assessment 37
V. 1 Overview 37
V. 2 Strategic Pipeline Assessment 37
V. 3 GIST Therapeutics Pipeline - Pipeline by Phases of Development 37
V. 3.1 GIST Therapeutics - Phase III Pipeline 37
V. 3.2 GIST Therapeutics - Phase II Pipeline 38
V. 3.3 GIST Therapeutics - Phase I Pipeline 38
V. 3.4 GIST Therapeutics - Preclinical Pipeline 38
V. 3.5 Technology Trends Analytic Framework 39
V. 4 GIST Therapeutics - Pipeline by Mechanism of Action 41
V. 5 Molecule Profile for Promising Drugs Under Clinical Development 42
V. 5.1 Masitinib 42
V. 5.2 Tasigna (Nilotinib) 42
V. 5.3 Nexavar (Sorafenib) 43
V. 5.4 Regorafenib (BAY 73-4506) 44
V. 6 Key Takeaway 45

VI Gastrointestinal Stromal Tumor (GIST) Therapeutics: Clinical Trials Mapping 46
VI. 1 Clinical Trials by Country (US, EU5 and Japan) 46
VI. 2 Clinical Trials by Phase 47
VI. 3 Clinical Trials by Trial Status 48
VI. 4 Key Sponsors 49
VI. 5 Top Firms Participating in GIST Therapeutics Clinical Trials 51

VII Gastrointestinal Stromal Tumor (GIST) Therapeutics: Strategic Assessment 52
VII. 1 Key Events Impacting the Future March ket 52
VII. 2 GIST Therapeutics: Implications for Future March ket Competition 53

VIII Gastrointestinal Stromal Tumor (GIST) Therapeutics: Future Players 54
VIII. 1 Introduction 54
VIII. 2 Firms Profiles 55
VIII. 2.1 Pfizer Inc. 55
VIII. 2.2 November artis AG 61
VIII. 2.3 AB Science 67
VIII. 2.4 Bayer AG 67
VIII. 2.5 Other Firms in the GIST Therapeutics March ket 72

IX GIST Therapeutics: Licensing and Partnership Deals 74

X GIST Therapeutics: Appendix 76
X. 1 March ket Definitions 76
X. 2 Abbreviations 76
X. 3 Research Methodology 77
X. 3.1 Coverage 77
X. 3.2 Secondary Research 77
X. 3.3 Forecasted data ing 78
X. 3.4 Primary Research 80
X. 3.5 Expert Panel Validation 80
X. 4 Contact Us 80
X. 5 Disclaimer 80
X. 6 Bibliography 81

1.1 List of Data tables
Data table 1: Incidence of GIST in Seven Major March kets#, 2010 6
Data table 2: Occurrence Rate of Symptoms for GIST, 2010 7
Data table 3: TNM Staging, GIST, 2010 8
Data table 4: GIST Therapeutics March ket, Global, Sales (USD Million), 2005-2010 12
Data table 5: GIST Therapeutics March ket, Global, Forecasted data (USD Million), 2010-2017 13
Data table 6: GIST Therapeutics March ket, The US, Sales (USD Million), 2005-2010 14
Data table 7: GIST Therapeutics March ket, The US, Forecasted data (USD Million), 2010-2017 15
Data table 8: GIST Therapeutics March ket, France, Sales (USD Million), 2005-2010 16
Data table 9: GIST Therapeutics March ket, France, Forecasted data (USD Million), 2010-2017 17
Data table 10: GIST Therapeutics March ket, Germany, Sales (USD Million), 2005-2010 18
Data table 11: GIST Therapeutics March ket, Germany, Forecasted data (USD Million), 2010-2017 19
Data table 12: GIST Therapeutics March ket, Italy, Sales (USD Million), 2005-2010 20
Data table 13: GIST Therapeutics March ket, Italy, Forecasted data (USD Million), 2010-2017 21
Data table 14: GIST Therapeutics March ket, Spain, Sales (USD Million), 2005-2010 22
Data table 15: GIST Therapeutics March ket, Spain, Forecasted data (USD Million), 2010-2017 23
Data table 16: GIST Therapeutics March ket, the UK, Sales (USD Million), 2005-2010 24
Data table 17: GIST Therapeutics March ket, the UK, Forecasted data (USD Million), 2010-2017 25
Data table 18: GIST Therapeutics March ket, Japan, Sales (USD Million), 2005-2010 26
Data table 19: GIST Therapeutics March ket, Japan, Forecasted data (USD Million), 2010-2017 27
Data table 20: Sutent - GIST Efficacy Results 36
Data table 21: GIST Therapeutics - Phase III Pipeline, 2011 37
Data table 22: GIST Therapeutics - Phase II Pipeline, 2011 38
Data table 23: GIST Therapeutics - Phase I Pipeline, 2011 38
Data table 24: GIST Therapeutics - Preclinical Pipeline, 2011 38
Data table 25: Nexavar Phase II Trial - Summary of Results, 2011 44
Data table 26: GIST Therapeutics - Clinical Trials by Country, 2011 46
Data table 27: GIST Therapeutics - Clinical Trials by Phase, 2011 47
Data table 28: GIST Therapeutics - Clinical Trials by Status, 2011 48
Data table 29: GIST Therapeutics - Key Sponsors, 2011 50
Data table 30: GIST Therapeutics - Top Firms Participating in Therapeutics Clinical Trials, 2011 51
Data table 31: Pfizer Inc. - Oncology, Pipeline, 2010 57
Data table 32: Pfizer Deals, from 2009 to 2010 58
Data table 33: November artis - Oncology Pipeline, 2010 63
Data table 34: November artis Deals, from 2009 to 2010 64
Data table 35: AB Science - Oncology Pipeline, 2010 67
Data table 36: AB Science Deals, 2010 67
Data table 37: Bayer AG - Oncology Pipeline, 2010 69
Data table 38: Bayer AG Deals, from 2009 to 2010 70
Data table 39: GIST Therapeutics March ket - Future Players 72
Data table 40: GIST Therapeutics, Global, Deals 74

1.2 List of Charts

Chart 1: GIST Therapeutics March ket, Global, Sales (USD Million), 2005-2010 12
Chart 2: GIST Therapeutics March ket, Global, Forecasted data (USD Million), 2010-2017 13
Chart 3: GIST Therapeutics March ket, The US, Sales (USD Million), 2005-2010 14
Chart 4: GIST Therapeutics March ket, The US, Forecasted data (USD Million), 2010-2017 15
Chart 5: GIST Therapeutics March ket, France, Sales (USD Million), 2005-2010 16
Chart 6: GIST Therapeutics March ket, France, Forecasted data (USD Million), 2010-2017 17
Chart 7: GIST Therapeutics March ket, Germany, Sales (USD Million), 2005-2010 18
Chart 8: GIST Therapeutics March ket, Germany, Forecasted data (USD Million), 2010-2017 19
Chart 9: GIST Therapeutics March ket, Italy, Sales (USD Million), 2005-2010 20
Chart 10: GIST Therapeutics March ket, Italy, Forecasted data (USD Million), 2010-2017 21
Chart 11: GIST Therapeutics March ket, Spain, Sales (USD Million), 2005-2010 22
Chart 12: GIST Therapeutics March ket, Spain, Forecasted data (USD Million), 2010-2017 23
Chart 13: GIST Therapeutics March ket, the UK, Sales (USD Million), 2005-2010 24
Chart 14: GIST Therapeutics March ket, the UK, Forecasted data (USD Million), 2010-2017 25
Chart 15: GIST Therapeutics March ket, Japan, Sales (USD Million), 2005-2010 26
Chart 16: GIST Therapeutics March ket, Japan, Forecasted data (USD Million), 2010-2017 27
Chart 17: Opportunity and Unmet Need in the GIST Therapeutics March ket 29
Chart 18: GIST Therapeutics - Strategic Competitor Assessment, 2010 31
Chart 19: Gleevec Phase III Trial Results - Progression-Free Survival 33
Chart 20: Gleevec Phase III Trial Results - Overall Response Rate 34
Chart 21: Sutent - Time to Tumor Progression in GIST Patients 36
Chart 22: GIST Therapeutics - Pipeline by Phase of Development, 2010 37
Chart 23: GIST Therapeutics - Technology Trends Analytic Framework, 2011 39
Chart 24: GIST Therapeutics - Technology Trends Analytic Framework - Description, 2011 40
Chart 25: GIST Therapeutics - Pipeline by Mechanism of Action, 2011 41
Chart 26: GIST Therapeutics - Clinical Trials by Country, 2011 46
Chart 27: GIST Therapeutics - Clinical Trials by Phase, 2011 47
Chart 28: GIST Therapeutics - Clinical Trials by Status, 2011 48
Chart 29: GIST Therapeutics - Overall Sponsors, 2011 49
Chart 30: GIST Therapeutics - Key Sponsors, 2011 49
Chart 31: GIST Therapeutics - Top Firms Participating in Therapeutics Clinical Trials, 2011 51
Chart 32: GIST Therapeutics March ket, Drivers and Restraints 2010 52
Chart 33: Implications for Future March ket Competition in the GIST Therapeutics March ket, 2010 53
Chart 34: GIST Therapeutics March ket - Pipeline by Firms, 2010 54
Chart 35: GlobalData March ket Forecasted data ing Model 79Pfizer Inc.
November artis AG
AB Science
Bayer AG

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Inflammation - Pipeline Review, H1 2014

Inflammation - Pipeline Review, H1 2014

  • $ 2 500
  • Company report
  • June 2014
  • by Global Markets Direct

Inflammation - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Inflammation - Pipeline Review, H1 2014', provides an overview of the Inflammation's therapeutic pipeline. This report provides ...

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • April 2014
  • by Global Markets Direct

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Corcept Therapeutics Incorporated - Product Pipeline Review - 2014', provides an overview of the Corcept ...

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

- Product Pipeline Review - H2 2011” provides a detailed overview on the ImmunoCellular Therapeutics, Ltd.’s research and development focus. The report includes information on current developmental ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.